GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs - PubMed
5 hours ago
- #weight loss
- #GLP-1 receptor agonists
- #obesity
- Systematic review and network meta-analysis comparing GLP-1 receptor/dual agonists for weight loss in overweight/obese adults with and without Type 2 diabetes.
- 127 RCTs analyzed, involving 58,976 participants (39,520 with T2DM, 19,456 without).
- Tirzepatide and subcutaneous semaglutide (Semaglutide_SC) were most effective for ≥5% and ≥10% weight loss in both T2DM and non-T2DM groups.
- Tirzepatide showed superior weight reduction compared to oral and subcutaneous semaglutide in T2DM and was the only effective agent in non-T2DM.
- Higher doses of GLP-1RAs enhanced weight loss but increased adverse events like nausea/vomiting, particularly with tirzepatide.
- Optimal dosing and adherence are crucial for achieving clinically meaningful weight loss with GLP-1 receptor/dual agonists.